Autism Diagnostic Observation Schedule (ADOS) in Unequal and Low-Resource Systems of Care
- 1Department of Child and Adolescent Psychiatry, İhsan Doğramacı Children's Hospital, Hacettepe University School of Medicine, Ankara, Türkiye
- 2Department of Pediatrics, Division of Developmental Medicine, and Department of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, Massachusetts, USA
- 3Department of Pediatrics and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
Abstract
The Autism Diagnostic Observation Schedule (ADOS) and its second edition (ADOS-2) have acquired a de facto "gold standard" status for reliably diagnosing autism in the United States, even though the developers themselves emphasize that the instrument should be used as part of a holistic, clinically driven developmental assessment. This narrative review is informed by diagnostic accuracy studies and the global mental health relevance of ADOS/ADOS-2 to low- and middle-income countries (LMICs) using Türkiye and the United States as point of contrast. We consider the benefits of ADOS/ADOS-2 —its contribution to standardized observation, cross-site comparability, and detailed phenotyping in research and complex clinical cases—as well as its limitations, including extensive training requirements, time-intensive administration, high kit costs, proprietary licensing, and tightly regulated translation policies. These factors substantially limit the practicality of routine ADOS/ADOS-2 use in LMICs and other resource-constrained settings, where most autistic children live. In the United States, ADOS/ADOS-2 based assessments have become deeply integrated into specialty services and, in some regions, even informally mandated by insurers or school systems, with consequences for wait times, access, and equity. In Türkiye, autism is primarily diagnosed through clinical assessment by child and adolescent psychiatrists without formal requirements for ADOS/ADOS-2, which expands clinical autonomy but results in less standardization and weaker cross-site consistency. We argue that treating the ADOS/ADOS-2 as a universal diagnostic "gold standard" is unachievable given the global public health resource constraints in LMICs. Autism diagnosis, service eligibility, and research, especially in such a poor resource setting will require scalable, open-access, and cost-effective tools for both routine care and population-level studies.
Related
- Cervical leukoplakia in Ghana: Unveiling diagnostic challenges and informing low-resource screening strategies
- Polar Seabed Observation Systems reveal winter diel rhythms and environmental drivers of euphausiids in Great Wall Bay, Antarctic Peninsula
- Modeling resource conflict and inequality in fragile systems: A spatial agent-based framework with a Uganda case study
- Risk assessment and climate adaptation research for agricultural cultivation and water resource systems within rural green production models
- Longitudinal analysis of vaccine-associated alterations in the faecal microbiota of layer chickens using a vaccination schedule representative of commercial practice
BibTeX
@article{adıguzel2026autism,
title = {{Autism Diagnostic Observation Schedule (ADOS) in Unequal and Low-Resource Systems of Care}},
author = {Setenay Adıgüzel and Kerim M. Munir},
journal = {Psychiatry and clinical psychopharmacology},
year = {2026},
month = aug,
doi = {10.65801/pcp.3484},
url = {https://europepmc.org/article/PMC/PMC13720792},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Autism Diagnostic Observation Schedule (ADOS) in Unequal and Low-Resource Systems of Care
AU - Setenay Adıgüzel
AU - Kerim M. Munir
PY - 2026
DA - 2026/08/01
JO - Psychiatry and clinical psychopharmacology
DO - 10.65801/pcp.3484
UR - https://europepmc.org/article/PMC/PMC13720792
AB - The Autism Diagnostic Observation Schedule (ADOS) and its second edition (ADOS-2) have acquired a de facto "gold standard" status for reliably diagnosing autism in the United States, even though the developers themselves emphasize that the instrument should be used as part of a holistic, clinically driven developmental assessment. This narrative review is informed by diagnostic accuracy studies and the global mental health relevance of ADOS/ADOS-2 to low- and middle-income countries (LMICs) using Türkiye and the United States as point of contrast. We consider the benefits of ADOS/ADOS-2 —its contribution to standardized observation, cross-site comparability, and detailed phenotyping in research and complex clinical cases—as well as its limitations, including extensive training requirements, time-intensive administration, high kit costs, proprietary licensing, and tightly regulated translation policies. These factors substantially limit the practicality of routine ADOS/ADOS-2 use in LMICs and other resource-constrained settings, where most autistic children live. In the United States, ADOS/ADOS-2 based assessments have become deeply integrated into specialty services and, in some regions, even informally mandated by insurers or school systems, with consequences for wait times, access, and equity. In Türkiye, autism is primarily diagnosed through clinical assessment by child and adolescent psychiatrists without formal requirements for ADOS/ADOS-2, which expands clinical autonomy but results in less standardization and weaker cross-site consistency. We argue that treating the ADOS/ADOS-2 as a universal diagnostic "gold standard" is unachievable given the global public health resource constraints in LMICs. Autism diagnosis, service eligibility, and research, especially in such a poor resource setting will require scalable, open-access, and cost-effective tools for both routine care and population-level studies.
SN - 2475-0581
ER -